These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
445 related articles for article (PubMed ID: 32351447)
1. Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes. Yang Y; Zhao C; Ye Y; Yu M; Qu X Front Endocrinol (Lausanne); 2020; 11():190. PubMed ID: 32351447 [TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis. Li D; Shi W; Wang T; Tang H Diabetes Obes Metab; 2018 Aug; 20(8):1972-1976. PubMed ID: 29573110 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study. Han SJ; Ha KH; Lee N; Kim DJ Diabetes Obes Metab; 2021 Mar; 23(3):682-691. PubMed ID: 33236515 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials. Yang Y; Pan H; Wang B; Chen S; Zhu H Chin Med Sci J; 2017 Apr; 32(1):22-7. PubMed ID: 28399981 [TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Fadini GP; Bonora BM; Mayur S; Rigato M; Avogaro A Diabetes Obes Metab; 2018 Mar; 20(3):740-744. PubMed ID: 29053207 [TBL] [Abstract][Full Text] [Related]
6. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337 [TBL] [Abstract][Full Text] [Related]
7. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Lam CSP; Ramasundarahettige C; Branch KRH; Sattar N; Rosenstock J; Pratley R; Del Prato S; Lopes RD; Niemoeller E; Khurmi NS; Baek S; Gerstein HC Circulation; 2022 Feb; 145(8):565-574. PubMed ID: 34775781 [TBL] [Abstract][Full Text] [Related]
8. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials. Lee MMY; Petrie MC; McMurray JJV; Sattar N Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025 [TBL] [Abstract][Full Text] [Related]
9. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Xu B; Li S; Kang B; Zhou J Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469 [TBL] [Abstract][Full Text] [Related]
10. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918 [TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus. Fralick M; Colacci M; Thiruchelvam D; Gomes T; Redelmeier DA Diabetes Obes Metab; 2021 Apr; 23(4):950-960. PubMed ID: 33336894 [TBL] [Abstract][Full Text] [Related]
12. Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Singh M; Sharma R; Kumar A Curr Drug Saf; 2019; 14(2):87-93. PubMed ID: 30727912 [TBL] [Abstract][Full Text] [Related]
13. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. Davidson JA; Sloan L Adv Ther; 2017 Jan; 34(1):41-59. PubMed ID: 27854055 [TBL] [Abstract][Full Text] [Related]
16. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Min SH; Yoon JH; Hahn S; Cho YM Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214 [TBL] [Abstract][Full Text] [Related]
17. Effects of Additional Administration of a Selective Inhibitor of Sodium Glucose co-transporter-2 Inhibitor on the Glycemic Control in Japanese Type 2 Diabetes Mellitus Patients Receiving Treatment with a Dipeptidyl Peptidase-4 Inhibitor. Kusunoki M; Sato D; Sakazaki T; Miyata T; Tsutsumi K; Oshida Y Drug Res (Stuttg); 2020 Apr; 70(4):131-136. PubMed ID: 32164029 [TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review. Escobar C; Barrios V; Cosín J; Gámez Martínez JM; Huelmos Rodrigo AI; Ortíz Cortés C; Torres Llergo J; Requeijo C; Solà I; Martínez Zapata MJ Diabet Med; 2021 Mar; 38(3):e14502. PubMed ID: 33368612 [TBL] [Abstract][Full Text] [Related]
19. Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis. Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC) Lancet Diabetes Endocrinol; 2021 Dec; 9(12):825-836. PubMed ID: 34656210 [TBL] [Abstract][Full Text] [Related]
20. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. van Baar MJB; van Ruiten CC; Muskiet MHA; van Bloemendaal L; IJzerman RG; van Raalte DH Diabetes Care; 2018 Aug; 41(8):1543-1556. PubMed ID: 30030256 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]